Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories · page 1 of 5
Destiny Pharma's anti-infective impresses against skin superbugs
With several potential treatments for serious infections currently in development, Destiny Pharma PLC has therefore found itself in an enviable position.